After 20 years on the market, AbbVie’s dry-eye drug Restasis to be available as generic
By
Alicia Lasek
Feb 03, 2022
Dry eyes affect nearly 19% percent of adults aged 75 years and older, according to data from a national survey.
FDA OKs first injectable antibody drug to prevent COVID-19 in high-risk patients
By
Alicia Lasek
Dec 10, 2021
One dose of injectable Evusheld may be effective for 6 months, FDA says. The drug neutralizes all previous SARS-CoV-2 variants, and AstraZeneca says it is working to establish its efficacy against the...
FDA approves virtual reality system for treatment of chronic back pain
By
Alicia Lasek
Nov 17, 2021
EaseVRx is designed for home use and is available by prescription to patients with clinically diagnosed lower back conditions, FDA says.
FDA approves first-ever eye drop that corrects age-related vision loss
By
Alicia Lasek
Nov 02, 2021
The new drug, Vuity, adjusts pupil size and corrects near vision without affecting distance vision, drugmaker Allergan says.
FDA approves first nasal spray for chronic dry eyes
By
Alicia Lasek
Oct 19, 2021
Sprayed twice daily into each nostril, Tyrvaya reduced eye dryness within four weeks in clinical trials. The medication will be available by prescription beginning in November, the developer says.
Alzheimer’s drug designed for ‘at-home’ use scores FDA breakthrough designation
By
Alicia Lasek
Oct 12, 2021
The experimental Alzheimer’s drug gantenerumab is the “first and only” anti-amyloid antibody being investigated for subcutaneous administration and could potentially be given to patients...
A first? COVID antibody therapy with full-year protection is up for FDA authorization
By
Alicia Lasek
Oct 08, 2021
Drugmaker AstraZeneca has asked the FDA to authorize what it says could be the first long-acting monoclonal antibody drug therapy for the prevention of COVID-19 in at-risk patients.
Merck to seek emergency use for COVID-19 antiviral pill that cuts severe outcomes by 50 percent
By
Alicia Lasek
Oct 04, 2021
Molnupiravir has reduced COVID-19 deaths and hospitalizations by half in a new clinical trial. An orally delivered drug could offer unprecedented treatment convenience, the drug’s developers say.
Drugmakers ask FDA to approve another Alzheimer’s drug, similar to Aduhelm
By
Alicia Lasek
Sep 29, 2021
Drugmakers Eisai and Biogen are putting the Food and Drug Administration to the test with a request to approve a second Alzheimer’s drug that works like aducanumab (Aduhelm), the new, yet controversial,...
First biosimilar approved for macular degeneration, other eye conditions
Sep 23, 2021
Biosimilar to Lucentis approved to treat neovascular age-related macular degeneration, macular edema, myopic choroidal neovascularization